KR920703003A - 혈관활성 바소토신 유도체 - Google Patents

혈관활성 바소토신 유도체

Info

Publication number
KR920703003A
KR920703003A KR1019920702039A KR920702039A KR920703003A KR 920703003 A KR920703003 A KR 920703003A KR 1019920702039 A KR1019920702039 A KR 1019920702039A KR 920702039 A KR920702039 A KR 920702039A KR 920703003 A KR920703003 A KR 920703003A
Authority
KR
South Korea
Prior art keywords
vasothocin
hgn
phe
derivatives
derivative according
Prior art date
Application number
KR1019920702039A
Other languages
English (en)
Other versions
KR0171614B1 (ko
Inventor
칼요한 아우렐
페르 멜린
앤더스 닐슨
저지 트로이나르
Original Assignee
페링 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페링 에이비 filed Critical 페링 에이비
Publication of KR920703003A publication Critical patent/KR920703003A/ko
Application granted granted Critical
Publication of KR0171614B1 publication Critical patent/KR0171614B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

혈관활성 바소토신 유도체
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 다음과 같은 식을 가지는 바소토신 유도체.
    [이 식에서, Hmp=2-히드록시-3-메르캅토프로피온산 잔기Z=페닐알라닌(Phe) 또는 티노신(Try) Y=호모글루타민(Hgn) 또는 호모시툴린(Hci)Q=H 또는 1-3개의 아미노산 잔기로서 같거나 다른 천연 또는 비천연 L-또는 D-아미노산이며 n=1,2 또는 3이다.]
  2. 제1항에 있어서, Z=Phe, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  3. 제1항에 있어서, Z=Phe, Y=Hgn, n=2이며 Q는 알라닐인 것을 특징으로 하는 비소토신 유도체.
  4. 제1항에 있어서, Z=Phe, Y=Hgn, n=2이며 Q는 L-2-아미노부티릴인것을 특징으로 하는 바소토신 유도체.
  5. 제1항에 있어서, Z=Phe, Y=Hci, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  6. 제l항에 있어서, Z=Tyr, Y=Hgn, n=3이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  7. 제1항에 있어서, Z=Tyr, Y=Hgn, n=2이며 Q는 H인 것을 특징으로 하는 바소토신 유도체.
  8. 활성성분으로서 1종이상의 제1항에 따르는 바소토신유도체와 함께 약제학적으로 허용 가능한 부가물 및/또는 희석제를 함유하는 것을 특징으로 하는 약제조성물.
  9. 제8항에 있어서, 비경구적 투여에 적합한 제제형태인 것을 특징으로 하는 약제조성물.
  10. 제9항에 있어서, 정맥내 투여에 적합한 용액의 형태인 것을 특징으로 하는 약제조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920702039A 1990-02-27 1991-02-26 혈관활성 바소토신 유도체 KR0171614B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9000691A SE502644C2 (sv) 1990-02-27 1990-02-27 Vasoaktiva vasotocinderivat
SE9000691.7 1990-02-27
PCT/SE1991/000154 WO1991013092A1 (en) 1990-02-27 1991-02-26 Vasoactive vasotocin derivatives

Publications (2)

Publication Number Publication Date
KR920703003A true KR920703003A (ko) 1992-12-17
KR0171614B1 KR0171614B1 (ko) 1999-02-01

Family

ID=20378692

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702039A KR0171614B1 (ko) 1990-02-27 1991-02-26 혈관활성 바소토신 유도체

Country Status (19)

Country Link
US (1) US5459236A (ko)
EP (1) EP0517778B1 (ko)
JP (1) JP2957275B2 (ko)
KR (1) KR0171614B1 (ko)
AT (1) ATE137764T1 (ko)
AU (1) AU633198B2 (ko)
CA (1) CA2076749C (ko)
DE (1) DE69119409T2 (ko)
DK (1) DK0517778T3 (ko)
ES (1) ES2089196T3 (ko)
FI (1) FI109703B (ko)
HU (1) HU215121B (ko)
IE (1) IE62345B1 (ko)
IL (1) IL97298A (ko)
MC (1) MC2254A1 (ko)
NO (1) NO923333L (ko)
RU (1) RU2067586C1 (ko)
SE (1) SE502644C2 (ko)
WO (1) WO1991013092A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
PT710243E (pt) * 1993-06-29 2000-11-30 Ferring Bv Sintese melhorada de peptidos ciclicos.
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
US8883965B2 (en) 2006-02-10 2014-11-11 Ferring B.V. Compounds
US9050286B2 (en) * 2007-08-14 2015-06-09 Ferring B.V. Use of peptidic vasopression receptor agonists
RU2454426C1 (ru) * 2011-04-06 2012-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Пептид калий-уретический
KR101304427B1 (ko) 2011-04-12 2013-09-05 한국과학기술연구원 재사용이 용이한 기공체 - 위성 나노입자 복합체 및 그 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
SE469473B (sv) * 1987-10-07 1993-07-12 Ferring Ab Vasoaktiva peptider

Also Published As

Publication number Publication date
WO1991013092A1 (en) 1991-09-05
NO923333D0 (no) 1992-08-26
FI109703B (fi) 2002-09-30
FI923820A0 (fi) 1992-08-26
CA2076749C (en) 2001-02-20
AU633198B2 (en) 1993-01-21
ES2089196T3 (es) 1996-10-01
EP0517778A1 (en) 1992-12-16
HUT61580A (en) 1993-01-28
US5459236A (en) 1995-10-17
SE9000691D0 (sv) 1990-02-27
IE62345B1 (en) 1995-01-25
DK0517778T3 (da) 1996-08-19
IL97298A (en) 1995-08-31
IE910648A1 (en) 1991-08-28
HU215121B (hu) 1998-09-28
AU7342491A (en) 1991-09-18
CA2076749A1 (en) 1991-08-28
JP2957275B2 (ja) 1999-10-04
NO923333L (no) 1992-10-16
DE69119409D1 (de) 1996-06-13
MC2254A1 (fr) 1993-03-25
JPH05504575A (ja) 1993-07-15
FI923820A (fi) 1992-08-26
ATE137764T1 (de) 1996-05-15
RU2067586C1 (ru) 1996-10-10
DE69119409T2 (de) 1996-09-05
HU9202748D0 (en) 1992-12-28
KR0171614B1 (ko) 1999-02-01
SE9000691L (sv) 1991-08-28
SE502644C2 (sv) 1995-11-27
EP0517778B1 (en) 1996-05-08
IL97298A0 (en) 1992-05-25

Similar Documents

Publication Publication Date Title
EP0528312A3 (en) Cyclic peptides and use thereof
HUP0100100A2 (hu) Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
AU8729791A (en) Pharmaceutical formulations
IL122754A0 (en) Cyclosporin derivatives their preparation and pharmaceutical compositions containing them
CA2004991A1 (en) Deletion analogues of magainin peptides
KR920703003A (ko) 혈관활성 바소토신 유도체
KR940005669A (ko) 사이클로펩타이드, 및 점막에 적용시 흡수 촉진제로서의 이의 용도
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
KR930002373A (ko) 헥사펩티드
RU92016593A (ru) Новый полипептид со сродством с липополисахаридами и фармацевтическая композиция для ингибирования вич на его основе
DE69630583D1 (de) Peptide, bronchodilator und den blutstrom verbesserndes mittel
ATE89264T1 (de) Arzneimittel enthaltend nitroxyalkylamine mit amidfunktion und verfahren zur herstellung dieser verbindungen.
KR920701242A (ko) 환원된 비가역성 봄베신 길항제
ATE91286T1 (de) Gefaessaktive peptide.
ES2074264T3 (es) Esteres de aminoacidos de la hidroquinona, su procedimiento de preparacion y composiciones farmaceuticas o cosmeticas que los contienen.
KR960037045A (ko) B형 바이러스(hbv)성 간염의 예방 및 치료용 약학적 제제

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021015

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee